Kadota Jun-ichi, Mukae Hiroshi, Tomono Kazunori, Kohno Shigeru, Nasu Masaru
Department of Infectious Diseases, Division of Pathogenesis and Disease Control, Oita University Faculty of Medicine, 1-1 Hasama, Oita 879-5593, Japan.
Int J Antimicrob Agents. 2004 Dec;24(6):550-4. doi: 10.1016/j.ijantimicag.2004.07.012.
This study compared the clinical characteristics and the effects of long-term macrolide antibiotic therapy of HLA-B54-positive and -negative cases in patients with diffuse panbronchiolitis (DPB). Thirty-two Japanese patients were enrolled who had the clinical criteria for DPB. All patients received long-term macrolide therapy, and therapeutic results were compared according to the presence or the absence of HLA-B54 antigen. Clinical, laboratory, radiological and bacterial features were strikingly similar in both groups before macrolide therapy. Long-term treatment with macrolides improved clinical symptoms, PaO(2), and forced expiratory volume in 1s (FEV(1)) equally in both groups. This study indicates that genetic susceptibility may not explain the pathogenesis of DPB, and that low-dose macrolide therapy can achieve clinical improvement irrespective of genetic predisposition in DPB.
本研究比较了弥漫性泛细支气管炎(DPB)患者中HLA - B54阳性和阴性病例的临床特征及长期大环内酯类抗生素治疗的效果。32例符合DPB临床标准的日本患者被纳入研究。所有患者均接受长期大环内酯类治疗,并根据HLA - B54抗原的有无比较治疗结果。在大环内酯类治疗前,两组患者的临床、实验室、影像学及细菌学特征极为相似。两组患者长期使用大环内酯类治疗均能同等程度地改善临床症状、动脉血氧分压(PaO₂)及一秒用力呼气容积(FEV₁)。本研究表明,遗传易感性可能无法解释DPB的发病机制,并且低剂量大环内酯类治疗无论DPB患者的遗传易感性如何均可实现临床改善。